Premature ovarian insufficiency: diagnosis, causes, treatment and fertility
Key Takeaways
Premature ovarian insufficiency is not diagnosed from a low AMH result alone. Before age 40, the diagnostic criteria include irregular or absent cycles for at least four months and an FSH above 25 IU/L; a repeat test is useful when the picture is uncertain. Care addresses fertility as well as bone, cardiovascular, sexual and psychological health.
Key evidence: International ESHRE-ASRM-CRE-WHiRL-IMS guideline on POI (2024) ASRM committee opinion on evaluating amenorrhoea (2024) PROVA randomised trial of ovarian PRP in poor responders (2024)
Understanding premature ovarian insufficiency
The original video is in French. An English-dubbed audio track and English subtitles are available; Arabic audio and subtitles are also provided.
A low AMH result or a change in menstrual cycles before the age of 40 can prompt an immediate fear: “Is this early menopause? Can I still have a child?” These are reasonable questions, but one blood result cannot answer them on its own.
Premature ovarian insufficiency, or POI, requires a structured assessment. It affects fertility, but it can also influence bone, cardiovascular, sexual and psychological health. Good care therefore goes beyond discussing pregnancy and includes protecting health over the longer term.
Contents
- What is premature ovarian insufficiency?
- Which symptoms should prompt assessment?
- How is POI diagnosed?
- Why investigate the cause?
- Why does care extend beyond fertility?
- What is the role of hormone therapy?
- Can pregnancy still occur?
- Ovarian PRP, stem cells and “rejuvenation”
- What should follow-up include?
- Frequently asked questions
What is premature ovarian insufficiency?
POI means that ovarian activity has been lost or substantially reduced before the age of 40. It may involve irregular or absent periods, a raised follicle-stimulating hormone (FSH), and reduced oestrogen production.
“Early menopause” is often used in everyday conversation, but it is not an exact synonym. Ovarian activity can fluctuate in POI, and occasional ovulation may still occur. This does not mean that fertility is normal, but it also means that pregnancy is not automatically impossible.
Older studies suggested that POI affected about 1% of women under 40. More recent publications estimate a prevalence closer to 3.5%, although figures vary between populations.
These numbers do not determine an individual diagnosis. Symptoms, menstrual history and appropriate investigations matter more than a population estimate.
Which symptoms should prompt assessment?
POI should be considered in a woman under 40 whose periods become irregular or stop, particularly when this change is accompanied by symptoms of oestrogen deficiency:
- hot flushes or night sweats;
- disrupted sleep;
- vaginal dryness or discomfort;
- pain during sex;
- reduced sexual desire;
- difficulty conceiving;
- changes in mood or concentration.
These symptoms are not specific to POI. Pregnancy should first be excluded. The ASRM opinion on amenorrhoea also highlights other causes of absent or irregular periods, including thyroid disorders, hyperprolactinaemia, polycystic ovary syndrome, a major change in weight, intensive exercise and some chronic illnesses.
Hormonal contraception can conceal or alter menstrual patterns and may lower FSH. A clinician may need to adjust the timing of tests. Do not stop prescribed treatment or contraception without discussing it with the clinician managing your care.
How is POI diagnosed?
The 2024 international guideline uses two diagnostic criteria:
- irregular or absent spontaneous cycles for at least four months; and
- an FSH concentration above 25 IU/L.
FSH does not have to be tested on a particular day of the cycle. One raised result may be sufficient when the menstrual history and clinical picture agree. If the result does not fit the history, or uncertainty remains, FSH should be repeated after four to six weeks.
Low oestradiol supports the presence of hypo-oestrogenism when FSH is raised, but oestradiol alone should not be used to diagnose POI.
Does a low AMH mean that I have POI?
No. Anti-Müllerian hormone (AMH) provides information about the follicle pool, but it should not be used as the primary diagnostic test for POI. It can be helpful when FSH results and the clinical picture remain inconclusive.
| Test or finding | What it can show | What it cannot establish alone |
|---|---|---|
| Menstrual history | A sustained change in cycles | The cause of that change |
| FSH | A core part of POI diagnosis | When a future ovulation will occur |
| AMH | Ovarian reserve in clinical context | POI, infertility or impossibility of natural pregnancy |
| Oestradiol | Evidence supporting oestrogen deficiency | POI diagnosis by itself |
| Ultrasound | Ovarian and pelvic anatomy | The future course of ovarian function with certainty |
Clinical note from Dr Senai Aksoy: when cycles remain regular
In a woman under 40 with a very low AMH but regular cycles, Dr Senai Aksoy first separates two different questions.
Diminished ovarian reserve mainly describes a reduced follicle pool: AMH and the antral follicle count may be low while endocrine ovarian function remains preserved. A clear rise in gonadotrophins, particularly an FSH concentration above 25 IU/L, instead warrants a targeted assessment for POI.
Regular cycles mean that the formal diagnostic criteria for POI have not yet been met. This is a discordant result that needs confirmation and clinical context, not a POI diagnosis made from FSH alone.
Because the picture is uncertain, Dr Aksoy favours repeating FSH after four to six weeks. This is consistent with the international recommendation to repeat testing when diagnostic uncertainty remains.
Low oestradiol strengthens concern about reduced ovarian steroid production but is not diagnostic by itself. Assessment becomes more important when there are symptoms of oestrogen deficiency or risk factors such as a family history of POI, an FMR1 premutation, a chromosomal disorder or Turner mosaicism, autoimmune disease, gonadotoxic treatment or bilateral ovarian surgery.
Why investigate the cause?
Finding a cause can change follow-up, inform relatives and influence health or fertility decisions. Even after appropriate investigation, however, no specific cause is identified in many women.
Treatment-related causes
Some chemotherapy, radiotherapy and ovarian surgery can damage ovarian function. Whenever feasible, the ESHRE fertility-preservation guideline supports discussing fertility preservation before gonadotoxic treatment without delaying urgent care.
Genetic causes
For non-iatrogenic POI, chromosomal analysis and FMR1 premutation testing are recommended. Broader genetic panels may be offered in some centres after comprehensive genetic counselling.
Genetic findings can have implications for the woman and sometimes for relatives. Their purpose and possible consequences should be discussed before and after testing.
Autoimmune causes
When the cause is unknown, testing for 21-hydroxylase antibodies is recommended to assess adrenal autoimmunity. Thyroid-stimulating hormone (TSH) should also be checked at diagnosis and repeated according to the guideline and clinical symptoms.
Anti-ovarian antibodies should not be used to diagnose autoimmune POI. Routine thyroid peroxidase antibody screening is also not recommended for every patient because positive results are common in the general population.
Why does care extend beyond fertility?
Long-term oestrogen deficiency before age 40 may affect health in ways that are not immediately visible. Follow-up should therefore extend beyond menstrual cycles.
Bone health
POI is associated with reduced bone mineral density and a higher risk of osteoporosis. A DXA bone-density scan is recommended at diagnosis where available. The timing of repeat scans depends on the first result, individual risk factors and adherence to hormone therapy.
Weight-bearing exercise, muscle strengthening, avoiding smoking, and adequate calcium and vitamin D intake support bone health. Supplements are not automatic; they depend on dietary intake and whether a deficiency is present.
Cardiovascular and metabolic health
Untreated POI is associated with increased long-term cardiovascular risk. A lipid profile and screening for diabetes should be performed at diagnosis. Blood pressure, weight and smoking status should then be reviewed at least annually, while further testing depends on the initial results and overall cardiovascular risk.
Sexual health, mood and quality of life
Vaginal dryness, pain, sleep disturbance and the news of reduced fertility can carry a substantial emotional burden. These difficulties are not minor or “only psychological”.
They deserve direct discussion, appropriate medical options and, if the woman wishes, psychological or psychosexual support.
What is the role of hormone therapy?
Unless contraindicated, hormone therapy is generally recommended until the usual age at menopause, even when hot flushes are mild. Its purpose is to replace part of the hormone exposure that would normally have been present and reduce the consequences of early oestrogen deficiency.
Treatment is individualised. Oestrogen may be given orally or through the skin. A woman with an intact uterus also needs a progestogen to protect the endometrium. The regimen depends on symptoms, medical history, preferences, the need for contraception and individual risk.
Evidence from women who reach menopause at the usual age should not simply be transferred to a young woman with POI. Replacing hormones that are absent too early has a different benefit-risk context.
Hormone therapy for POI is not contraception. If pregnancy is not wanted, an appropriate contraceptive method should be discussed. A history of hormone-sensitive cancer, thrombosis or another complex condition requires specialist assessment.
Can pregnancy still occur?
POI substantially reduces the chance of conceiving using a woman’s own eggs. In non-surgical POI, however, ovarian activity may be intermittent, so occasional ovulation and natural conception can still occur. It is not possible to predict reliably who will ovulate or when.
No medicine, supplement or stimulation protocol has been shown to restore ovarian activity reliably or increase natural conception rates in POI.
Fertility counselling should begin with the woman’s own priorities. Depending on the situation, discussion may include:
- individualised monitoring when intermittent ovarian activity is seen;
- in selected cases, a specialist discussion about ovarian stimulation, with a clear explanation that it is not a validated treatment for restoring ovarian function or improving natural conception;
- use of eggs or embryos frozen before ovarian function declined;
- donor eggs, an established medical route where local law and access allow;
- other family-building options according to personal choices and the legal framework.
Pregnancy after POI also warrants preconception assessment, particularly when a genetic, cardiac or treatment-related cause has been identified.
Ovarian PRP, stem cells and “rejuvenation”: what do we know?
Intraovarian platelet-rich plasma (PRP), stem cells and products such as exosomes are sometimes described as ways to “wake up” the ovaries. That language goes beyond the current evidence.
Some uncontrolled PRP studies report changes in AMH, FSH or follicle counts. These surrogate markers do not prove that more babies are born.
The randomised PROVA trial studied women with poor ovarian response, not POI. It found no significant improvement in mature egg yield, euploid embryos or sustained implantation.
A retrospective cohort that included women with POI found no increase in clinical pregnancy or live birth after PRP.
A 2025 meta-analysis reported changes in ovarian markers and pregnancies across heterogeneous studies. Because much of the evidence was non-randomised, these pooled results do not show that PRP improves live birth compared with no treatment.
These approaches should remain experimental and be studied in properly governed research. Women need clear information about uncertainty, procedural risks, costs and alternatives. Experimental treatment should not delay indicated hormone therapy or realistic fertility counselling.
What should follow-up include?
A clear plan helps prevent care from becoming a series of disconnected tests. It may include:
- confirming the diagnosis and excluding other causes of cycle disturbance;
- investigating genetic, treatment-related or autoimmune causes as appropriate;
- discussing hormone therapy and contraception separately;
- assessing bone health and cardiovascular risk;
- treating vaginal, sexual, sleep or mood symptoms;
- clarifying fertility goals and realistically available options;
- arranging continuing review even when symptoms are mild.
The aim is not to reduce a woman to an FSH or AMH value. Results need to be interpreted alongside age, menstrual history, medical history, priorities and overall health.
Frequently asked questions
Does a very low AMH mean that I am menopausal?
No. A very low AMH suggests a small follicle pool, but it does not diagnose POI or menopause. Menstrual history, FSH and clinical context must be considered together.
Does POI make natural pregnancy impossible?
No, but the chance is substantially reduced and unpredictable. Intermittent ovarian activity may occur. No current treatment can guarantee or reliably trigger its return.
Does hormone therapy prevent pregnancy?
Hormone therapy prescribed for POI is not contraception. If pregnancy is not wanted, contraception should be discussed. If pregnancy is desired, the hormone regimen and follow-up can be reviewed with the treating clinician.
Must a raised FSH always be checked twice?
Not always. One FSH result above 25 IU/L may support diagnosis when the menstrual and clinical criteria agree. A repeat result after four to six weeks is useful when uncertainty remains.
Is ovarian PRP a validated treatment for POI?
No. Current evidence does not show a reliable improvement in live birth, and ovarian PRP remains experimental.
Related reading
- A complete guide to egg freezing
- Ovarian PRP: evidence and limitations
- Stem cells and fertility: scientific promise or established treatment?
- Exosomes and ovarian regeneration: understanding the current limits
Sources
- Panay N, Anderson RA, Nappi RE, et al. Evidence-based guideline: premature ovarian insufficiency. Human Reproduction Open. 2024;2024(4):hoae065. Read the international guideline
- American Society for Reproductive Medicine. Current evaluation of amenorrhea: a committee opinion. 2024. Read the ASRM opinion
- ESHRE Guideline Group on Female Fertility Preservation. ESHRE guideline: female fertility preservation. Human Reproduction Open. 2020;2020(4):hoaa052. Read the guideline
- Herlihy NS, Cakiroglu Y, et al. Effect of intraovarian platelet-rich plasma injection on IVF outcomes in women with poor ovarian response: the PROVA randomized controlled trial. Human Reproduction. 2024. doi:10.1093/humrep/deae093. View the PubMed record
- Tülek F, et al. The effects of intra-ovarian autologous platelet rich plasma injection on IVF outcomes of poor responder women and women with premature ovarian insufficiency. Journal of the Turkish German Gynecological Association. 2022. View the PubMed record
- Sadeghpour S, Maleki F, Hajizadeh-Sharafabad F, Ghasemnejad-Berenji H. Evaluation of intraovarian injection of platelet-rich plasma for enhanced ovarian function and reproductive success in women with POI and POR: a systematic review and meta-analysis. European Journal of Medical Research. 2025;30(1):610. doi:10.1186/s40001-025-02854-3. View the PubMed record
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.